AstraZeneca/Ionis’s Eplontersen Shows Competitive Efficacy In ATTR Polyneuropathy At 66 Weeks

US FDA Approval Pending With Decision Due In December

 
• By Mandy Jackson
many blue targets and three arrows hitting the center of the first one
Eplontersen met all three co-primary endpoints at 66 weeks • Source: Shutterstock

More from Clinical Trials

More from R&D